Lemborexant (Dayvigo) Overdose Severity
Lemborexant overdose has limited published clinical experience, so exact lethality risk is not well quantified. [1] Reported human toxicity after overdose most often involves central nervous system (CNS) depression manifested as sedation or decreased consciousness, with supportive care used in case reports. [1][2] Severe outcomes including death have been reported in isolated case reports, often without reliable information on co-ingestants or exact dose. [3]
Toxicity Pattern Observed in Reported Cases
The most consistently described effect in overdose is CNS depression with somnolence and impaired alertness. [1][2] In a published overdose case with estimated very high exposure (720 mg lemborexant plus 78 mg eszopiclone), mild CNS depression occurred (Glasgow Coma Scale 11) with hemodynamic stability and spontaneous clinical improvement with supportive care. [2] A fatal autopsy case has been reported with detectable blood levels of lemborexant, with cause attributed to acute lemborexant poisoning based on postmortem findings. [3]
Overdose Management Recommendations
No specific antidote for lemborexant overdose is identified in the available labeled overdose information. [1] Overdose management is supportive care with close medical supervision, with consideration of multiple drug involvement when other substances may have been co-ingested. [1] Poison Control contact is recommended for up-to-date overdose management guidance in the prescribing information. [1]
Key Evidence: Survival Despite High Ingestion
A case report described survival after an estimated 720 mg lemborexant ingestion (plus eszopiclone), with mild CNS depression and improvement without targeted intervention beyond supportive care. [2] Serial plasma measurements in that report showed a peak lemborexant concentration at 9 hours after ingestion while the patient clinically recovered. [2]
Key Evidence: Fatal Overdose Report
A fatal case report described a decedent found dead in whom postmortem testing identified lemborexant in blood and stomach contents. [3] The report provides measured concentrations but does not establish a population-level lethal dose threshold. [3]
Practical Danger Assessment in Real-World Terms
The danger in suspected lemborexant overdose is driven by CNS depression severity, aspiration risk from impaired airway protection, and co-ingestion with other sedatives or alcohol. [1] Even when lethal toxicity is not guaranteed, overdose should be treated as potentially serious because fatal outcomes have been documented and exact dose-to-severity relationships are not established. [1][3]
Initiation Thresholds for Emergency Evaluation
Immediate emergency evaluation is recommended for any suspected overdose with impaired alertness, inability to stay awake, repeated vomiting, breathing difficulty, or suspected co-ingestion with other sedatives or alcohol. [1] Urgent Poison Control consultation is recommended for suspected overdose because management guidance is time-sensitive and depends on timing, dose estimate, and co-ingestants. [1]
Common Pitfalls to Avoid
Relying on the expectation of “low toxicity” is a pitfall because death has been reported and labeled experience with overdose is limited. [1][3] Assuming overdose will resolve without observation is a pitfall because CNS depression can impair airway protection and recovery may be delayed depending on timing and co-ingestants. [1][2]
Targets and Goals After Overdose
The goal of care is maintenance of airway, breathing, and circulation with monitoring for persistent or worsening CNS depression in a supervised setting. [1] The goal of consultation with Poison Control is selection of appropriate monitoring and supportive interventions based on the specific exposure history. [1]
When the Question Indicates Active Harm
If a suspected Dayvigo overdose is ongoing or the person is difficult to awaken or has breathing concerns, emergency services should be contacted immediately. [1]